Q-omics provides the consensus-scored IL17RB profile across patient tissues and cancer cell-line models. IL17RB expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL17RB is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, IL17RB RNA expression shows 19,606 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where IL17RB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17RB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17RB survival associations across molecular data types. IL17RB RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17RB RNA expression–survival associations across cancer types. High IL17RB expression shows unfavorable associations in LIHC and ACC, but favorable associations in KIRC, COAD, SKCM and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL17RB RNA expression.
This table summarizes IL17RB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IL17RB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17RB shows lower tumor expression in KICH and higher tumor expression in STAD, LIHC, READ, COAD and UCEC. The KICH box plot shows higher IL17RB RNA expression in normal versus tumor tissue (log2 FC = −3.538, t-test p < 0.001).
This table shows molecular features associated with IL17RB in patient tissues and cancer cell lines. In patient samples, IL17RB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17RB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
